Palo Alto, California, USA, November 16, 2026
Fortvita Biologics has received its first positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for Zybrivo® (sintilimab) in combination with chemotherapy for the first-line treatment of eligible adults with advanced non-squamous non-small cell lung cancer (NSCLC). The recommendation marks an important European regulatory milestone for Fortvita, a member of the Innovent Group, and could expand treatment options for patients across the European region if the European Commission grants final marketing authorization. The positive CHMP opinion was adopted on November 12, 2026, and announced by Fortvita on November 16. It is supported by results from the Phase 3 ORIENT-11 clinical trial, which evaluated sintilimab alongside pemetrexed and platinum-based chemotherapy in patients with locally advanced, metastatic, or recurrent non-squamous NSCLC. The study demonstrated improvements in progression-free survival and overall survival compared with chemotherapy alone. Sintilimab is a fully human IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), an immune checkpoint that can limit the body’s ability to recognize and attack cancer cells. By blocking PD-1 interactions with its ligands PD-L1 and PD-L2, the treatment is designed to strengthen antitumour immune responses. The recommendation represents progress in Fortvita’s strategy to expand access to Innovent-developed medicines beyond China.
CHMP Recommends Zybrivo for Advanced NSCLC
The CHMP recommendation covers Zybrivo in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with non-squamous NSCLC who have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Eligible patients include those with locally advanced disease who are not candidates for curative-intent surgery or chemoradiation, as well as patients with metastatic disease. The recommendation is significant because lung cancer remains a major cause of cancer-related mortality, and advanced NSCLC continues to require effective systemic treatment options. Sintilimab works through an immunotherapy mechanism rather than directly targeting tumour DNA or inhibiting cancer-cell growth through conventional chemotherapy pathways. Blocking the PD-1 immune checkpoint can help restore T-cell activity against cancer cells, making checkpoint inhibitors an important component of modern oncology treatment. The CHMP’s positive opinion is an important regulatory step, but it is not the final marketing authorization. The European Commission is expected to make the final decision in the coming months. If authorization is granted, the approval would apply across the 27 European Union member states and the European Economic Area countries Iceland, Norway, and Liechtenstein.
Phase 3 ORIENT-11 Trial Demonstrates Survival Benefits
The regulatory recommendation is based on ORIENT-11 (NCT03607539), a randomized, multicentre, double-blind, placebo-controlled Phase 3 study involving 397 adults with locally advanced, metastatic, or recurrent non-squamous NSCLC. Participants had no EGFR or ALK genomic tumour aberrations, regardless of their PD-L1 expression status. Patients were randomized in a 2:1 ratio to receive either sintilimab or placebo, each combined with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent radiological review committee. Results showed that sintilimab plus chemotherapy reduced the hazard of disease progression or death by 52% compared with placebo plus chemotherapy. Median PFS was 8.9 months versus 5.0 months, respectively. The combination also demonstrated a 35% reduction in the hazard of death, with median overall survival (OS) reaching 24.2 months compared with 16.8 months in the control group. These findings provide clinical evidence supporting the use of sintilimab alongside chemotherapy in the studied patient population. The reported safety profile was consistent with the known profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified in the study.
Fortvita Expands Its European Oncology Strategy
The positive CHMP opinion is Fortvita’s first major European regulatory milestone and supports its broader strategy to bring Innovent’s medicines to patients outside China. The company is responsible for advancing the development and commercialization of Innovent’s medicines in international markets, working alongside its partners. Sintilimab has already received approvals for multiple indications in China, including several cancers, and has been used in approximately three million patients there, according to Innovent’s company-reported data. The potential European authorization of Zybrivo would represent an important step in expanding the international reach of the antibody therapy. The European Commission’s final decision remains pending, and the medicine should not be described as approved for this European indication until that decision is issued. Overall, the CHMP recommendation and Phase 3 ORIENT-11 results highlight continued progress in immunotherapy-based treatment development for advanced lung cancer.
Source: Fortvita Biologics press release



